7 terminated, 4 completed, 2 recruiting, 1 active not recruiting. 12 Phase 1, 12 Phase 2, 1 Phase 3.
Follow Wave Life Sciences USA, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy WVE-N531 - Duchenne Muscular Dystrophy | Phase 2 | Enrolling by invitation | Wave Life Sciences USA, Inc. | 175 | 2025-12-28 | 2026-03-06 |
| A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity WVE-007 - Overweight and Obesity | Phase 1 / Phase 2 | Recruiting | Wave Life Sciences USA, Inc. | 400 | 2025-01-31 | 2026-10-26 |
| A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD WVE-006 - Alpha-1 Antitrypsin Deficiency | Phase 1 / Phase 2 | Recruiting | Wave Life Sciences USA, Inc. | 48 | 2024-07-19 | 2026-10-19 |
| A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) WVE-006 - Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1 | Completed | Wave Life Sciences USA, Inc. | 47 | 2023-11-14 | 2026-03-23 |
| Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) WVE-004 10 mg Q12W - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 8 | 2022-12-14 | 2026-09-09 |
| Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) WVE-N531 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Active not recruiting | Wave Life Sciences USA, Inc. | 25 | 2021-09-28 | 2026-10-19 |
| Study of WVE-003 in Patients With Huntington's Disease SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003 - Huntington Disease | Phase 1 / Phase 2 | Completed | Wave Life Sciences USA, Inc. | 47 | 2021-09-06 | 2025-08-12 |
| Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) WVE-004, Placebo - ALS, FTD | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 35 | 2021-06-28 | 2023-10-23 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 27 | 2020-04-13 | 2022-02-09 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 36 | 2019-09-24 | 2022-02-09 |
| Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy WVE-210201 (suvodirsen), Placebo - Duchenne Muscular Dystrophy | Phase 2 / Phase 3 | Terminated | Wave Life Sciences USA, Inc. | 6 | 2019-09-04 | 2021-05-20 |
| Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families Duchenne Muscular Dystrophy, Burden, Dependency | Completed | Jett Foundation, Inc. | 60 | 2018-09-20 | 2019-04-01 | |
| Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy WVE-210201, Placebo - Duchenne Muscular Dystrophy | Phase 1 | Completed | Wave Life Sciences USA, Inc. | 36 | 2018-01-24 | 2019-04-08 |
| Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 61 | 2017-07-17 | 2022-02-10 |
| Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102, Placebo - Huntington's Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 88 | 2017-07-17 | 2022-04-25 |
Huntington Disease (5) · Muscular Dystrophy, Duchenne (5) · alpha 1-Antitrypsin Deficiency (2) · Amyotrophic Lateral Sclerosis (1) · Frontotemporal Dementia (1) · Obesity (1) · Overweight (1) · Rare Diseases (1)
Sagittal Abdominal Diameter (1)
United Kingdom (14) · Canada (9) · Australia (7) · France (7) · Germany (6) · United States (6) · Denmark (5) · Poland (5) · Netherlands (4) · Belgium (3) · Italy (3) · Jordan (2) · New Zealand (2) · Sweden (2) · Czechia (1)
Michael A Panzara, MD, MPH (2) · Christine McSherry, R.N. (1) · Cynthia Caracta, MD (1)